{"url_path":"/sec/atos/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-213423-index.html","accession_number":"0001193125-26-213423","cik":"0001488039","ticker":"ATOS","issuer_name":"ATOSSA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-213423-index.html","primary_entity_key":"0001488039","primary_entity_name":"ATOSSA THERAPEUTICS, INC."},"word_count":47,"has_tables":true,"body_markdown":"ITEM 5. OTHER INFORMATION\n\n(c) Trading Plans\n\nDuring the three months ended March 31, 2026, no director or Section 16 officer adopted, modified, or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).\n\n \n\n47"}